Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07829406
PHASE1

A Study to See How Safe a New Medicine (NNC0642-1895) is in Healthy People

Sponsor: Novo Nordisk A/S

View on ClinicalTrials.gov

Summary

This study is testing a new medicine, in healthy adults to assess its safety and understand how it behaves in the body. The purpose of this study is to evaluate the safety, tolerability, and how the body responds to a single dose of NNC0642-1895 in healthy adults. Participant will either get study medicine (NNC0642-1895) or placebo (a treatment that has no active medicine in it). Which treatment a participant receives is decided by chance. NNC0642-1895 is a new medicine that is being tested in humans for the first time and is not currently available for doctors to prescribe. The study will last for about 94 days (approximately 14 weeks).

Official title: A First in Human Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Intravenous Administrations of NNC0642-1895 in Healthy Adults

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

148

Start Date

2026-09-17

Completion Date

2027-09-12

Last Updated

2026-09-21

Healthy Volunteers

Yes

Interventions

DRUG

NNC0642-1895

NNC0642-1895 will be administered intravenously.

DRUG

Placebo

Placebo will be administered intravenously.

Locations (1)

ICON-Salt Lake City

Salt Lake City, Utah, United States